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CASE REPORT
Efficacy of pazopanib and sunitinib 
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Abstract 
Background: Chordomas are rare malignant tumours of the axial skeleton and skull base supposed to arise from 
cellular remnants of the notochord. These tumours have the potential to metastasize (30–40 %), usually in the later 
course of the disease. However, the greatest morbidity is usually a result of loco-regional recurrence with infiltration 
and destruction of surrounding bone and soft tissue. Patients with unresectable or metastatic chordoma are faced 
with a poor prognosis since cytotoxic chemotherapy or other systemic therapies have not proven their efficacy yet. 
However, several molecularly targeted drugs have been proposed as potentially beneficial, including tyrosine kinase 
inhibitors (TKIs) directed at vascular endothelial growth factor receptor (VEGFR), like pazopanib and sunitinib.
Case presentation: Five patients with unresectable or metastatic chordoma were treated with VEGFR inhibitors paz-
opanib or sunitinib in the Leiden University Medical Centre (LUMC) between 2008 and 2015. Two out of four patients 
treated with pazopanib derived clinical benefit and disease remained stable for respectively 14 and 15 months. The 
one patient treated with sunitinib achieved a partial response according to RECIST 1.1 which lasted for a total of 
27 months. No serious adverse events were observed.
Conclusion: These results on the use of pazopanib and sunitinib in chordoma are promising, with an objective 
response on sunitinib and a median progression free interval of 8.5 months (range 3–15 months), comparable to 
that of imatinib, in the pazopanib subgroup. However further research is needed to assess the definite role of VEGFR 
inhibitors in chordoma.
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Background
Chordomas are rare malignant bone tumours of the axial 
skeleton and skull base that have a prevalence of less 
than 1/100,000 [1]. They are supposed to arise from cel-
lular remnants of the notochord that persist during foe-
tal development [2]. These tumours have the potential 
to metastasize (30–40  %), usually in the later course of 
the disease. However, the greatest morbidity is generally 
a result of loco-regional recurrence with infiltration and 
destruction of surrounding bone and soft tissue [2–4].
The first consensus guidelines for the diagnosis and 
treatment of chordoma were published in the Lancet 
Oncology in 2015 [4]. In patients with localized disease, 
complete surgical resection with adequate margins offers 
the best chance of long-term control. Definitive (proton 
beam) radiotherapy is the preferred alternative in case 
resection is not feasible. The addition of standard adju-
vant radiotherapy is recommended for skull base and 
cervical spine chordoma. In sacral chordoma the con-
sensus guidelines recommend consideration of radio-
therapy in case of R1 resection [4]. However, results from 
another retrospective patient series show that the time 
to recurrence is significantly longer with the addition of 
radiotherapy, accompanied by a trend towards longer 
overall survival, and thus support the strategy to add 
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radiotherapy as standard adjuvant therapy [5]. Ten-year 
local recurrence free survival rates after initial surgery is 
33–49 %. In case of loco-regional recurrence prognosis is 
poor and a number of palliative treatment modalities can 
be considered, e.g. (debulking) surgery and (stereotactic 
or heavy particle) radiation [4].
Cytotoxic chemotherapy or other systemic thera-
pies have not proven their efficacy and are therefore 
not recommended in any line of treatment [4]. A better 
molecular understanding of chordoma can be helpful to 
identify targetable pathways. So far, only systemic treat-
ment with the platelet derived growth factor receptor 
(PDGFR) tyrosine kinase inhibitor (TKI) imatinib has 
shown positive results in a phase 2 study in advanced 
chordoma. This trial included 56 patients of whom one 
(2  %) achieved a partial response according to RECIST 
1.1 and another 20  % a minor response. Median pro-
gression-free survival was 9 months. Moreover, 64 % of 
patients derived clinical benefit and 70 % of patients sta-
ble disease (SD) [6]. The positive results of this trial have 
led to funding for its use in chordoma patients in some 
countries.
Several other molecularly targeted drugs directed at 
pathways believed to be implicated in chordoma have 
been evaluated, including the epidermal growth factor 
receptor (EGFR)-inhibitors erlotinib, gefitinib and lapat-
inib, the mTOR (mechanistic target of rapamycin)-inhib-
itor sirolimus, and vascular endothelial growth factor 
(VEGF)-inhibitor bevacizumab. Most of these drugs have 
shown modest activity in case reports and case series, 
administered either as monotherapy or combined with 
other agents [7–13]. A dedicated phase 2 study of lapa-
tinib in EGFR-positive chordoma resulted in a progres-
sion free survival (PFS) of 8 months [14]. Furthermore, a 
phase 2 study on sorafenib in 27 patients with advanced 
and metastatic chordoma by the French Sarcoma Group, 
resulted in a 9-month progression free rate of 73 % and a 
12-month overall survival rate of 86.5 % [15].
The effect of pazopanib and sunitinib was only pub-
lished for a limited numbers of patients (pazopanib 1 
patient and sunitinib 9 patients) [16, 17]. These multi-tar-
geted kinase inhibitors not only inhibit PDFGR, but also 
the vascular endothelial growth factor receptor (VEGFR) 
considered relevant for chordoma progression.
Inhibition of pro-angiogenic growth factors like 
VEGFR may be relevant in chordoma genesis and pro-
liferation. Increased expression of established angiogen-
esis-related factors VEGF, hypoxia-inducible factor-1α 
(HIF-1α) and matrix metalloproteinase (MMP)-2 and 
-9 is observed in chordoma tissue and cell lines [18, 19]. 
Moreover, expression of MMP-9 was associated with an 
increased local recurrence rate and unfavourable prog-
nosis [19]. These findings highlight the important role of 
angiogenesis in chordoma, and VEGFR inhibitors could 
therefore be a promising therapeutic drug class.
This consecutive case series reports the response of 
chordoma patients to VEGFR TKIs pazopanib and suni-
tinib. In the Leiden University Medical Centre, a total of 
five chordoma patients were treated with these agents 
between 2008 and 2015; four patients with pazopanib 
and one patient with sunitinib. The patients treated 
with pazopanib were part of the “TIP-study”, a prospec-
tive pharmacological study investigating the feasibility of 
pharmacokinetics (PK)-guided individualized dosing to 
reduce the interpatient variability in pazopanib exposure 
[20].
Cases
See Table 1 for an overview of patients, tumour charac-
teristics and results.
The first patient is a 47-year old male who was referred 
to our hospital for systemic treatment of a multifocal 
recurrence of his sacral chordoma. The chordoma was 
diagnosed 2  years earlier and treated with intralesional 
excision and cryosurgery, followed by postoperative 
radiotherapy (60 Gy, boost of 66 Gy presacral area of sus-
pected irradical resection). Pazopanib was started at a 
dose of 800 mg/day, and reduced to 600 mg/day 4 weeks 
later due to blood area under the curve (AUC) levels 
above the minimum threshold for activity [20, 21]. Over-
all, pazopanib was well tolerated; the patient reported 
loss of hair pigment, grade 1 skin rash on his legs, fatigue 
grade 2 and intermittent diarrhoea (maximum grade 2) 
for which he successfully used loperamide. The disease 
remained stable according to RECIST 1.1 (with scans 
approximately every 4  months) for 14  months until the 
patient noticed increasing back pain radiating to his 
left buttock. MRI scan showed progression of the sacral 
tumour mass. Since other tumour localizations remained 
stable, pazopanib was continued for another 6  months 
while a palliative sacral resection was scheduled. The 
patient died of progressive disease 9 months after resec-
tion and discontinuation of pazopanib.
Patient 2 is a 54-year old male who presented with coc-
cygodynia since a fall on his tail bone 10  years before. 
Initial imaging showed a chordoma of the sacrum with 
a maximum diameter of 18 cm, compressing the rectum 
and bladder (see Fig.  1a). Since the tumour had a close 
relationship to bladder, rectum and skin, resection was 
not deemed feasible and the patient was started on sys-
temic treatment with pazopanib (800  mg/day). After 
4  weeks of treatment the patient reported symptomatic 
improvement and he could taper his analgesic medica-
tion. Apart from grade 1 fatigue, no other pazopanib 
related side-effects were reported. CT scans at 4, 6 and 
10 months of treatment showed stable disease according 
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to RECIST 1.1. After 15  months however, there were 
clinical and radiological signs of progression (maximum 
diameter of 24  cm, see Fig.  1b). After extensive discus-
sion, patient declined en-bloc resection due to significant 
predicted morbidity. Since pazopanib was tolerated very 
well, treatment was continued for a total of 27  months 
until evident local disease progression. The patient chose 
a further palliative treatment course because of rapid 
deterioration of his condition, and he died 2 months later.
Patient 3 is a 66-year old male with a sacral chordoma 
diagnosed in 2010. Primary treatment, consisting of en-
bloc resection with adequate margins, was complicated 
by post-operative urosepsis and development of a large 
seroma. Scheduled adjuvant radiotherapy was omitted 
due to these complications. A multifocal local recurrence 
was diagnosed 2 years later and first line systemic treat-
ment with pazopanib (800  mg/day) started. The patient 
reported intermittent grade 1 nausea, but tolerated treat-
ment overall well. Unfortunately, progressive disease 
according to RECIST 1.1 was seen on MRI after only 
3 months of treatment. Pazopanib was discontinued and 
patient went on to have palliative radiotherapy on subcu-
taneous metastases (36 Gy). His disease is clinically stable 
since radiotherapy treatment in March 2013, although 
MRI scans do show progression of existing lesions.
The fourth and last patient treated with pazopanib is a 
42-year old male with a chordoma of the spine, primary 
lesion in corpus of Th11 with associated myelum com-
pression. He was diagnosed 3 years before and underwent 
three consecutive intralesional resections with stereotac-
tic radiotherapy (39  Gy) after the first surgery. He pre-
sented in our hospital with progressive intraspinal and 
hepatic metastases after 9 months of systemic treatment 
with imatinib. Second line treatment with pazopanib was 
started at a dose of 800 mg/day, and patient was tempo-
rarily dose reduced to 600 mg/day due to elevated AUC 
levels. Aside from grade 1 haemoptysis, related to an inci-
dental pulmonary embolism, no other side-effects were 
reported. Three months after the start of pazopanib, this 
patient was hospitalized with acute paraplegia second-
ary to progressive spinal lesions (RECIST 1.1 progressive 
disease). Pazopanib was discontinued and there were no 
further surgical or radiotherapy options for this patient. 
He died a year later as a result of disease progression.
The fifth patient, a 59-year old female with a chordoma 
of corpus L1, was treated with sunitinib. She underwent 
three intralesional resections, adjuvant radiotherapy 
(60  Gy) and systemic treatment with imatinib during 
6  months until progression. The MRI scan before the 
start of sunitinib treatment showed a large retroperi-
toneal metastasis with a maximum diameter of 11  cm 
(anterior posterior [AP] measurement, see Fig. 2a). Suni-
tinib was commenced at a dose of 50  mg/day (4  weeks 
on, 2  weeks off), and lowered to 37.5  mg/day due to 
on-going grade 2 nausea. Other reported symptoms 
include: intermittent grade 2 fatigue, grade 1 hand-foot 
syndrome, grade 1 epistaxis and grade 2 thrombocytope-
nia. Follow-up MRI scans after 3 and 6 months showed 
a partial response according to RECIST 1.1 within the 
retroperitoneal lesion, shrinking down to maximum AP 
diameter of 7.5 cm (Fig. 2b). Further stabilization of dis-
ease lasted for 27  months. On progression, the patient 
was switched to imatinib and sirolimus combination 
treatment, which resulted in further tumour growth after 
Table 1 Overview patients treated with pazopanib and sunitinib
All pathology samples were reviewed and/or revised by pathologists at the LUMC/Dutch Committee on Bone Tumours. IHC staining for brachyury was only performed 
(and found to be positive) on the tumour sample for patient 1. Diagnosis was based on microscopy findings and IHC staining for pankeratin, keratin AE1/3, vimentin, 
S100 and/or MIB-1 for all patients
Pt Localization Prior local Tx Prior systemic Tx Drug/dose Results (RECIST 1.1 criteria) Adverse events







Rash gr 1, intermittent diar-
rhoea max gr 2, fatigue gr 2, 
loss pigment hair









PD 3 months Intermittent nausea and 
vomiting gr 1





PD 3 months, paraplegia –
5 Lumbar spine Intralesional excision 3x








Dose reduction due to gr 2 
nausea. Other symptoms: 
intermittent fatigue gr 2, 
hand-foot syndrome gr 1, 
epistaxis gr 1, thrombocyto-
penia gr 2
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4  months (Fig.  2c). The patient died due to progressive 
disease 18 months later.
Progression-free interval was defined as time from first 
dose of drug until date of confirmed radiological dis-
ease progression according to RECIST 1.1. All patients 
reached the RECIST 1.1 progressive disease endpoint. 
The mean progression-free interval for patients in the 
pazopanib group was 8.5 months and 14 months overall.
Discussion
This case series describes the effect of VEGFR TKIs pazo-
panib in four patients and sunitinib in one patient with 
unresectable or progressive chordoma treated in the Lei-
den University Medical Centre.
A partial response according to RECIST 1.1 was seen 
in the only patient using sunitinib and three out of five 
patients reported symptomatic improvement. The 
median progression free interval was 8.5  months in the 
pazopanib subgroup, 27  months in the patient treated 
with sunitinib and 14 months overall. Treatment was well 
tolerated with only mild to moderate side effects. In the 
pazopanib group patients reported the following side 
effects: skin rash (25 %), fatigue (50 %), diarrhoea (25 %) 
and nausea (25 %). The patient on sunitinib was treated 
Fig. 1 CT images of patient 2 treated with pazopanib. a CT scan at 
start of pazopanib showing a large sacral chordoma reaching from 
S2 to coccygis. Measurements: 20 × 16 × 13 cm (AP × LR × CC). b 
CT scan after 15 months of pazopanib showing progressive disease. 
Measurements: 21 × 24 × 23 cm (AP × LR × CC) Fig. 2 MRI images (T2 gadolinium and fat suppression) of patient 
5 treated with sunitinib. a MRI scan at start of sunitinib showing a 
large retroperitoneal metastasis of a primary lumbar spine chordoma. 
Measurements: 10.3 × 10.7 × 9.4 cm (LR × AP × CC). b MRI scan 
after 6 months of sunitinib showing a partial response according 
to RECIST 1.1. Measurements: 9.5 × 7.4 × 8.3 cm (LR × AP × CC). c 
MRI scan showing progressive disease after 27 months of treatment. 
Measurements: 8.9 × 10 cm (LR × AP)
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with a reduced dose due to on-going grade 2 nausea and 
experienced fatigue, hand-foot syndrome and thrombo-
cytopenia. The dose reductions in the pazopanib patients 
were solely based on blood drug levels as a part of the 
TIP study and were not a result of adverse events.
Side effects seen in our patients were expected and 
comparable to those seen in other populations [16, 22]. 
No serious adverse events were observed.
Limitations to this case series are primarily its ret-
rospective and unplanned analysis and small patient 
numbers. Response evaluation was not standardized as 
imaging was performed every 2–6 months for the differ-
ent patients.
However, results from small case series like this are 
important, since experience with the use of pazopanib 
and sunitinib in chordoma in literature reports is lim-
ited. A phase 2 trial of sunitinib in 53 patients with non-
gastrointestinal stromal tumour sarcomas included nine 
patients with chordoma. No radiological responses by 
RECIST 1.1 or metabolic responses by FDG-PET were 
seen, but four out of nine chordoma patients had stable 
disease for a period ranging from 17 to 70  weeks [16]. 
We could find only one Japanese case report on pazo-
panib used in chordoma. This patient achieved a partial 
response with a significant reduction in tumour size and 
was treated for a total of 14  months until progression 
[17].
Conclusion
The results from our case series on the use of VEGFR 
inhibitors pazopanib and sunitinib in chordoma are 
promising, with an partial response according to RECIST 
1.1 on sunitinib and a median PFS of 8.5 months, compa-
rable to that of imatinib [6], in the pazopanib subgroup. 
New treatment strategies are urgently needed for these 
patients with unresectable chordomas: a situation that 
can lead to severe morbidity and represents an unmet 
medical need. Large randomized trials will not be feasible 
due to the rarity of the disease. A definite role of VEGFR 
TKIs can only be established after a prospective phase II 
study, either randomized cross-over or compared to his-
torical controls aiming for at least 12 months PFS in first 
line or 9 months in second of later line after imatinib. We 
would like to challenge regulators, pharmaceutical indus-
try and sponsors to support such registration trials with 
VEGFR TKIs in this difficult disease state.
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